- Home
- BON vs QNTM Comparison
BON vs QNTM Comparison
Compare BON & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- QNTM
- Stock Information
- Founded
- BON 2006
- QNTM 1998
- Country
- BON China
- QNTM Canada
- Employees
- BON N/A
- QNTM N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- QNTM
- Sector
- BON Health Care
- QNTM
- Exchange
- BON Nasdaq
- QNTM NYSE
- Market Cap
- BON 9.9M
- QNTM 9.1M
- IPO Year
- BON 2021
- QNTM N/A
- Fundamental
- Price
- BON $1.58
- QNTM $5.10
- Analyst Decision
- BON
- QNTM
- Analyst Count
- BON 0
- QNTM 0
- Target Price
- BON N/A
- QNTM N/A
- AVG Volume (30 Days)
- BON 13.4K
- QNTM 66.2K
- Earning Date
- BON 11-29-2024
- QNTM 11-12-2024
- Dividend Yield
- BON N/A
- QNTM N/A
- EPS Growth
- BON N/A
- QNTM N/A
- EPS
- BON 2.19
- QNTM N/A
- Revenue
- BON $25,555,939.00
- QNTM N/A
- Revenue This Year
- BON $47.04
- QNTM N/A
- Revenue Next Year
- BON $77.63
- QNTM N/A
- P/E Ratio
- BON $0.67
- QNTM N/A
- Revenue Growth
- BON N/A
- QNTM N/A
- 52 Week Low
- BON $1.23
- QNTM $3.50
- 52 Week High
- BON $6.99
- QNTM $96.20
- Technical
- Relative Strength Index (RSI)
- BON 57.03
- QNTM 49.64
- Support Level
- BON $1.35
- QNTM $4.75
- Resistance Level
- BON $1.56
- QNTM $5.35
- Average True Range (ATR)
- BON 0.11
- QNTM 0.45
- MACD
- BON 0.02
- QNTM -0.04
- Stochastic Oscillator
- BON 82.41
- QNTM 32.64
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.